These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 9473791

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T, Nishizawa K, Mitsumori K.
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [Abstract] [Full Text] [Related]

  • 3. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
    Perachino M, Cavalli V, Bravi F.
    BJU Int; 2010 Mar; 105(5):648-51. PubMed ID: 19747358
    [Abstract] [Full Text] [Related]

  • 4. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
    Kotake T, Akaza H, Usami M, Naito S, Kanetake H, Taguchi T, Tsukagoshi S, Koiso K.
    Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
    [Abstract] [Full Text] [Related]

  • 5. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M, Chiba Prostate Study Group.
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [Abstract] [Full Text] [Related]

  • 6. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P).
    Berruti A, Cerutti S, Fasolis G, Sperone P, Tarabuzzi R, Bertetto O, Pagani G, Zolfanelli R, Pallotti S, Bumma C, Fontana D, Rosseti SR, Dogliotti L, Angeli A.
    Anticancer Res; 1997 Aug; 17(6D):4697-702. PubMed ID: 9494591
    [Abstract] [Full Text] [Related]

  • 7. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y, Fukui I.
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [Abstract] [Full Text] [Related]

  • 8. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
    Bong GW, Clarke HS, Hancock WC, Keane TE.
    Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
    [Abstract] [Full Text] [Related]

  • 9. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB, Mottet N.
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS, Pacificar JS, Shapiro CE, Williams SG.
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [Abstract] [Full Text] [Related]

  • 14. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
    Youssef E, Tekyi-Mensah S, Hart K, Bolton S, Forman J.
    Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
    [Abstract] [Full Text] [Related]

  • 15. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling.
    Wells A, Souto JC, Solava J, Kassis J, Bailey KJ, Turner T.
    Clin Cancer Res; 2002 Apr; 8(4):1251-7. PubMed ID: 11948140
    [Abstract] [Full Text] [Related]

  • 16. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A.
    Clin Cancer Res; 2004 Jul 01; 10(13):4398-405. PubMed ID: 15240528
    [Abstract] [Full Text] [Related]

  • 17. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H, Saika T, Tsushima T, Ebara S, Senoh T, Yamato T, Nasu Y, Kumon H.
    Prostate; 2006 Mar 01; 66(4):439-44. PubMed ID: 16329145
    [Abstract] [Full Text] [Related]

  • 18. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
    Bélanger A, Labrie F, Dupont A, Brochu M, Cusan L.
    Clin Invest Med; 1988 Oct 01; 11(5):321-6. PubMed ID: 2972431
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.